ATE500847T1 - Pegylierte g-csf-polypeptide und herstellungsverfahren dafür - Google Patents
Pegylierte g-csf-polypeptide und herstellungsverfahren dafürInfo
- Publication number
- ATE500847T1 ATE500847T1 AT06722962T AT06722962T ATE500847T1 AT E500847 T1 ATE500847 T1 AT E500847T1 AT 06722962 T AT06722962 T AT 06722962T AT 06722962 T AT06722962 T AT 06722962T AT E500847 T1 ATE500847 T1 AT E500847T1
- Authority
- AT
- Austria
- Prior art keywords
- pegylated
- csf polypeptides
- csf
- production method
- polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68672605P | 2005-06-01 | 2005-06-01 | |
PCT/DK2006/000292 WO2006128460A2 (en) | 2005-06-01 | 2006-05-26 | Pegylated g-csf polypeptides and methods of producing same |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE500847T1 true ATE500847T1 (de) | 2011-03-15 |
Family
ID=37308965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06722962T ATE500847T1 (de) | 2005-06-01 | 2006-05-26 | Pegylierte g-csf-polypeptide und herstellungsverfahren dafür |
Country Status (16)
Country | Link |
---|---|
US (5) | US7381805B2 (de) |
EP (1) | EP1888119B1 (de) |
JP (2) | JP5137821B2 (de) |
KR (1) | KR20080027291A (de) |
CN (1) | CN101193658B (de) |
AT (1) | ATE500847T1 (de) |
AU (1) | AU2006254543A1 (de) |
BR (1) | BRPI0611221A2 (de) |
CA (1) | CA2607844C (de) |
DE (1) | DE602006020562D1 (de) |
IL (1) | IL187009A0 (de) |
MX (1) | MX2007015156A (de) |
NO (1) | NO20075708L (de) |
RU (1) | RU2007149238A (de) |
WO (1) | WO2006128460A2 (de) |
ZA (1) | ZA200709704B (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0611221A2 (pt) | 2005-06-01 | 2010-08-24 | Maxygen Holdings Ltd | polipeptÍdeos de g-csf peguilados e mÉtodos de produÇço dos mesmos |
CN104689333B (zh) * | 2007-08-27 | 2018-05-29 | 拉蒂奥法姆有限责任公司 | G-csf 缀合物的液体制剂 |
CN102215876A (zh) * | 2008-09-19 | 2011-10-12 | 马克西根公司 | 通过施用多peg化的粒细胞集落刺激因子(g-csf)变体来治疗辐射诱发的嗜中性细胞减少症的方法 |
US7914828B2 (en) * | 2008-10-17 | 2011-03-29 | Levine Brian M | Combination herbal product to benefit respiratory tract |
TW201138831A (en) * | 2009-09-30 | 2011-11-16 | Prolong Pharmaceuticals Inc | Modified granulocyte colony stimulating factor (G-CSF) |
WO2011053545A1 (en) * | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Granulocyte-colony stimulating factor produced in glycoengineered pichia pastoris |
AR083006A1 (es) * | 2010-09-23 | 2013-01-23 | Lilly Co Eli | Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas |
WO2012064845A2 (en) * | 2010-11-09 | 2012-05-18 | Nektar Therapeutics | G-csf polymer conjugates having a releasable linkage |
EP2709669A1 (de) | 2011-05-17 | 2014-03-26 | Bristol-Myers Squibb Company | Verfahren zur aufrechterhaltung der pegylierung von polypeptiden |
CN104109199B (zh) * | 2013-04-16 | 2019-04-30 | 深圳未名新鹏生物医药有限公司 | 一种聚乙二醇单修饰的人粒细胞集落刺激因子的制备方法及其产品 |
CN107949565A (zh) * | 2015-06-11 | 2018-04-20 | 安姆生物制药有限责任公司 | 聚乙二醇化粒细胞集落刺激因子(gcsf) |
KR102020995B1 (ko) * | 2017-10-30 | 2019-09-16 | 한국코러스 주식회사 | 콜로니자극인자와 폴리올이 접합된 접합물을 고수율로 제조하는 방법 |
WO2020118136A1 (en) * | 2018-12-06 | 2020-06-11 | Board Of Regents, The University Of Texas System | Selectively cleavable therapeutic nanoparticles |
CN114853872B (zh) * | 2022-04-27 | 2023-11-17 | 山东新时代药业有限公司 | 一种聚乙二醇修饰rhG-CSF的制备方法 |
Family Cites Families (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US588025A (en) * | 1897-08-10 | Furnace-door-operating device | ||
WO1985000817A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
JPS61227526A (ja) | 1984-07-25 | 1986-10-09 | Chugai Pharmaceut Co Ltd | 新規なコロニー刺激因子 |
WO1986004605A1 (en) | 1985-02-08 | 1986-08-14 | Chugai Seiyaku Kabushiki Kaisha | Human granulocyte colony stimulating factor |
US6004548A (en) | 1985-08-23 | 1999-12-21 | Amgen, Inc. | Analogs of pluripotent granulocyte colony-stimulating factor |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
JPS6263335A (ja) | 1985-09-13 | 1987-03-20 | Fuji Photo Film Co Ltd | 化学反応情報の処理方法 |
ATE67517T1 (de) | 1985-09-30 | 1991-10-15 | Chugai Pharmaceutical Co Ltd | Menschlicher granulozyten-colony stimulierender faktor. |
ES2039209T5 (es) | 1986-01-22 | 1996-07-16 | Chugai Pharmaceutical Co Ltd | Compuesto farmaceutico que promueve el restablecimiento de la capacidad hemopoyetica. |
US4908773A (en) | 1987-04-06 | 1990-03-13 | Genex Corporation | Computer designed stabilized proteins and method for producing same |
DK203187A (da) | 1986-04-22 | 1987-10-23 | Immunex Corp | Human g-csf proteinekspression |
WO1988001297A1 (en) | 1986-08-11 | 1988-02-25 | Cetus Corporation | Expression of g-csf and muteins thereof |
US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
US5214132A (en) | 1986-12-23 | 1993-05-25 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
US5681720A (en) | 1986-12-23 | 1997-10-28 | Kyowa Hakko Co., Ltd. | DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide |
US5362853A (en) | 1986-12-23 | 1994-11-08 | Kyowa Hakko Kogyo Co., Ltd. | Polypeptide derivatives of human granulocyte colony stimulating factor |
DK174044B1 (da) | 1986-12-23 | 2002-05-06 | Kyowa Hakko Kogyo Kk | Polypeptid afledt fra human granulocytkolonistimulerende faktor, og fremgangsmåde til fremstilling deraf, DNA kodende for nævnte polypeptid, rekombinant plasmid indeholdende nævnte DNA, og mikroorganismer indeholdende nævnte rekombinante plasmid....... |
US4853871A (en) | 1987-04-06 | 1989-08-01 | Genex Corporation | Computer-based method for designing stablized proteins |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
GB2213821B (en) | 1987-12-23 | 1992-01-02 | British Bio Technology | Synthetic human granulocyte colony stimulating factor gene |
CA1340810C (en) | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
KR0133561B1 (ko) | 1988-05-13 | 1998-04-21 | 스티븐 엠. 오드레 | 과립구 군체 자극인자의 정제방법 |
ATE111921T1 (de) | 1988-06-03 | 1994-10-15 | Chugai Pharmaceutical Co Ltd | Menschlicher kristallinischer granulocyt- koloniestimulierungsfaktor und dessen herstellung. |
US5025388A (en) | 1988-08-26 | 1991-06-18 | Cramer Richard D Iii | Comparative molecular field analysis (CoMFA) |
US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
US5104651A (en) | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
US6166183A (en) | 1992-11-30 | 2000-12-26 | Kirin-Amgen, Inc. | Chemically-modified G-CSF |
US20020177688A1 (en) * | 1988-12-22 | 2002-11-28 | Kirin-Amgen, Inc., | Chemically-modified G-CSF |
DE68925966T2 (de) | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | Chemisch modifizierte granulocytenkolonie erregender faktor |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
US5109119A (en) | 1989-06-06 | 1992-04-28 | Schering Corporation | Crystalline r-h-gm-csf and method |
IE66494B1 (en) | 1989-09-26 | 1996-01-10 | Immunex Corp | Granulocyte-colony stimulating factor receptors |
AU641949B2 (en) | 1989-10-10 | 1993-10-07 | Amgen, Inc. | Compositions and methods for treating or preventing infections in canine and feline animals |
US5265030A (en) | 1990-04-24 | 1993-11-23 | Scripps Clinic And Research Foundation | System and method for determining three-dimensional structures of proteins |
GB9107846D0 (en) | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
US5399345A (en) | 1990-05-08 | 1995-03-21 | Boehringer Mannheim, Gmbh | Muteins of the granulocyte colony stimulating factor |
DE4014750A1 (de) | 1990-05-08 | 1991-11-14 | Boehringer Mannheim Gmbh | Muteine des granulozyten-stimulierenden faktors (g-csf) |
JP3249147B2 (ja) | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | 生理活性蛋白含有経口製剤 |
IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
ES2118756T5 (es) | 1990-08-29 | 2004-01-16 | Genetics Institute, Llc | Estimuladores de hematopoyesis de multiples dominios. |
US5124297A (en) | 1990-12-07 | 1992-06-23 | Amoco Corporation | Olefin polymerization and copolymerization catalyst |
DE4105480A1 (de) | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | Verbesserte aktivierung von rekombinanten proteinen |
US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
US5157736A (en) | 1991-04-19 | 1992-10-20 | International Business Machines Corporation | Apparatus and method for optical recognition of chemical graphics |
DE69231467T2 (de) | 1991-05-10 | 2001-01-25 | Genentech Inc | Auswählen von agonisten und antagonisten von liganden |
US5386507A (en) | 1991-07-18 | 1995-01-31 | Teig; Steven L. | Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof |
US5281698A (en) | 1991-07-23 | 1994-01-25 | Cetus Oncology Corporation | Preparation of an activated polymer ester for protein conjugation |
DE69227693T2 (de) * | 1991-08-30 | 1999-07-22 | Hutchinson Fred Cancer Res | Hybride cytokine |
JP2638359B2 (ja) | 1991-11-26 | 1997-08-06 | 富士通株式会社 | 分子動力学法の拘束条件作成装置 |
WO1993025687A1 (en) | 1992-06-09 | 1993-12-23 | Chiron Corporation | Crystallization of m-csf |
ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
US5772992A (en) | 1992-11-24 | 1998-06-30 | G.D. Searle & Co. | Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors |
DE69333243T2 (de) | 1992-11-24 | 2004-08-19 | G.D. Searle & Co., Chicago | Mutierte polypeptide des interleukin-3(il-3) |
US6057133A (en) | 1992-11-24 | 2000-05-02 | G. D. Searle | Multivariant human IL-3 fusion proteins and their recombinant production |
US6153183A (en) | 1992-11-24 | 2000-11-28 | G. D. Searle & Company | Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production |
US5738849A (en) | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
US5424963A (en) | 1992-11-25 | 1995-06-13 | Photon Research Associates, Inc. | Molecular dynamics simulation method and apparatus |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
DE69534676T2 (de) | 1994-02-08 | 2006-08-17 | Amgen Inc., Thousand Oaks | Orale Verabreichung von chemisch modifizierten Proteinen |
US6245900B1 (en) | 1994-02-23 | 2001-06-12 | Kyowa Hakko Kogyo Co., Ltd. | Platelet production promoting agent |
US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
AU4658596A (en) | 1995-02-03 | 1996-08-21 | G.D. Searle & Co. | Novel c-mpl ligands |
US6017523A (en) | 1995-06-06 | 2000-01-25 | G.D. Searle & Co. | Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides |
US6066318A (en) | 1995-10-05 | 2000-05-23 | G.D. Searle & Co. | Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors |
EP0870027A1 (de) | 1995-10-05 | 1998-10-14 | G.D. Searle & Co. | C-mpl rezeptoragonisten |
KR100456212B1 (ko) | 1995-10-05 | 2005-01-15 | 지.디. 썰 엘엘씨 | 다기능성조혈수용체아고니스트 |
US6100070A (en) | 1995-10-05 | 2000-08-08 | G. D. Searle & Co. | G-CSF receptor agonists |
CA2234042A1 (en) | 1995-10-05 | 1997-04-10 | G.D. Searle & Co. | Novel g-csf receptor agonists |
US6660257B1 (en) | 1996-10-25 | 2003-12-09 | Pharmacia Corporation | Circular permuteins of flt3 ligand |
IL129565A0 (en) | 1996-10-25 | 2000-02-29 | Searle & Co | Multi-functional chimeric hematopoietic receptor agonists |
US5969105A (en) | 1996-10-25 | 1999-10-19 | Feng; Yiqing | Stem cell factor receptor agonists |
NZ337911A (en) | 1997-04-11 | 2001-04-27 | G | flt3 ligand chimeric proteins |
KR100241257B1 (ko) | 1997-05-22 | 2000-02-01 | 한승수 | 인체 과립구 콜로니 자극 인자 활성물질 및 그것의 제조방법 |
ATE469166T1 (de) | 1997-06-06 | 2010-06-15 | Kyowa Hakko Kirin Co Ltd | Chemisch modifizierte polypeptide |
NZ502375A (en) | 1997-07-14 | 2001-11-30 | Bolder Biotechnology Inc | The addition of non-natural cysteine derivatives to cause the protein to act as antagonists of the GH family |
US5985263A (en) | 1997-12-19 | 1999-11-16 | Enzon, Inc. | Substantially pure histidine-linked protein polymer conjugates |
US6451986B1 (en) | 1998-06-22 | 2002-09-17 | Immunex Corporation | Site specific protein modification |
WO2000018905A1 (en) | 1998-09-25 | 2000-04-06 | G.D. Searle & Co. | Method of producing permuteins by scanning permutagenesis |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
JP4092081B2 (ja) | 1999-01-06 | 2008-05-28 | ゼンコー・インコーポレイテッド | 顆粒球形成活性を有するg−csf変異体相当核酸およびタンパク質 |
ES2204509T3 (es) | 1999-01-29 | 2004-05-01 | F. Hoffmann-La Roche Ag | Conjugados de gcsf. |
JP2000319298A (ja) | 1999-03-04 | 2000-11-21 | Seibutsu Bunshi Kogaku Kenkyusho:Kk | 蛋白質複合体の結晶、構造座標、及び構造座標の使用 |
KR100356140B1 (ko) | 1999-07-08 | 2002-10-19 | 한미약품공업 주식회사 | 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법 |
US6555660B2 (en) | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
ES2327606T3 (es) * | 2000-01-10 | 2009-11-02 | Maxygen Holdings Ltd | Conjugados de g-csf. |
US6831158B2 (en) | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
US6646110B2 (en) | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
WO2002020751A2 (en) | 2000-09-07 | 2002-03-14 | Eli Lilly And Company | Hyperglycosylated polypeptides |
US6946548B2 (en) | 2000-09-08 | 2005-09-20 | Massachusetts Institute Of Technology | G-CSF analog compositions and methods |
GB0022877D0 (en) | 2000-09-18 | 2000-11-01 | Isis Innovation | Analogues |
US20020142964A1 (en) | 2000-11-02 | 2002-10-03 | Nissen Torben Lauesgaard | Single-chain polypeptides |
WO2002036626A1 (en) * | 2000-11-02 | 2002-05-10 | Maxygen Aps | Single-chain multimeric polypeptides |
CN1214321C (zh) * | 2000-12-11 | 2005-08-10 | 皇家菲利浦电子有限公司 | 信号处理设备 |
NZ530545A (en) | 2001-07-11 | 2006-10-27 | Maxygen Holdings Ltd | Specific conjugates comprising a polypeptide exhibiting G-CSF activity and a non-polypeptide moiety |
BRPI0611221A2 (pt) | 2005-06-01 | 2010-08-24 | Maxygen Holdings Ltd | polipeptÍdeos de g-csf peguilados e mÉtodos de produÇço dos mesmos |
-
2006
- 2006-05-26 BR BRPI0611221-8A patent/BRPI0611221A2/pt not_active IP Right Cessation
- 2006-05-26 US US11/420,546 patent/US7381805B2/en not_active Expired - Fee Related
- 2006-05-26 JP JP2008513928A patent/JP5137821B2/ja not_active Expired - Fee Related
- 2006-05-26 CA CA2607844A patent/CA2607844C/en not_active Expired - Fee Related
- 2006-05-26 AT AT06722962T patent/ATE500847T1/de not_active IP Right Cessation
- 2006-05-26 KR KR1020077030982A patent/KR20080027291A/ko active IP Right Grant
- 2006-05-26 EP EP06722962A patent/EP1888119B1/de not_active Not-in-force
- 2006-05-26 AU AU2006254543A patent/AU2006254543A1/en not_active Abandoned
- 2006-05-26 WO PCT/DK2006/000292 patent/WO2006128460A2/en active Application Filing
- 2006-05-26 MX MX2007015156A patent/MX2007015156A/es unknown
- 2006-05-26 RU RU2007149238/13A patent/RU2007149238A/ru not_active Application Discontinuation
- 2006-05-26 CN CN2006800195588A patent/CN101193658B/zh not_active Expired - Fee Related
- 2006-05-26 DE DE602006020562T patent/DE602006020562D1/de active Active
- 2006-09-18 US US11/532,808 patent/US20070014762A1/en not_active Abandoned
- 2006-09-18 US US11/532,818 patent/US20070014763A1/en not_active Abandoned
-
2007
- 2007-04-30 US US11/742,551 patent/US20080167218A1/en not_active Abandoned
- 2007-04-30 US US11/742,445 patent/US7655766B2/en not_active Expired - Fee Related
- 2007-10-30 IL IL187009A patent/IL187009A0/en unknown
- 2007-11-08 NO NO20075708A patent/NO20075708L/no not_active Application Discontinuation
- 2007-11-12 ZA ZA200709704A patent/ZA200709704B/xx unknown
-
2012
- 2012-08-06 JP JP2012173959A patent/JP2013010765A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2007015156A (es) | 2008-02-15 |
NO20075708L (no) | 2008-02-27 |
DE602006020562D1 (de) | 2011-04-21 |
JP2013010765A (ja) | 2013-01-17 |
WO2006128460A3 (en) | 2007-03-01 |
BRPI0611221A2 (pt) | 2010-08-24 |
RU2007149238A (ru) | 2009-07-20 |
US20070014763A1 (en) | 2007-01-18 |
JP5137821B2 (ja) | 2013-02-06 |
EP1888119A2 (de) | 2008-02-20 |
EP1888119B1 (de) | 2011-03-09 |
AU2006254543A1 (en) | 2006-12-07 |
CN101193658B (zh) | 2011-08-31 |
US20070009478A1 (en) | 2007-01-11 |
US7655766B2 (en) | 2010-02-02 |
IL187009A0 (en) | 2008-02-09 |
CN101193658A (zh) | 2008-06-04 |
US7381805B2 (en) | 2008-06-03 |
WO2006128460A2 (en) | 2006-12-07 |
ZA200709704B (en) | 2008-11-26 |
CA2607844A1 (en) | 2006-12-07 |
US20080090764A1 (en) | 2008-04-17 |
US20070014762A1 (en) | 2007-01-18 |
JP2008542311A (ja) | 2008-11-27 |
US20080167218A1 (en) | 2008-07-10 |
CA2607844C (en) | 2012-07-10 |
KR20080027291A (ko) | 2008-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE500847T1 (de) | Pegylierte g-csf-polypeptide und herstellungsverfahren dafür | |
HK1205193A1 (en) | Recombinant n-glycosylated proteins from procaryotic cells n- | |
DK1317537T3 (da) | Sammensætninger og fremgangsmåder med G-CSF analoger | |
ATE448686T1 (de) | Actriib-fusionspolypeptide und verwendungen dafür | |
ATE540973T1 (de) | Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung | |
SG131109A1 (en) | Muteins of tear lipocalin | |
MX2009005455A (es) | (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano. | |
ATE390142T1 (de) | Synergistische zusammensetzung zur behandlung von diabetes mellitus | |
DK2027152T3 (da) | Peptidfragmenter til induktion af syntese af ekstracellulære matrixproteiner | |
MX2008012748A (es) | Un proceso para la concentracion de un polipeptido. | |
NZ603805A (en) | Methods for increasing and mobilizing hematopoietic stem cells | |
RU2013126581A (ru) | Мутанты стрептокиназы и их ковалентно модифицированные формы | |
EP1423414A4 (de) | Neue depsipeptide und verfahren zu deren herstellung | |
ATE367167T1 (de) | Aufbereitung von aldesleukin zur pharmazeutischen verwendung | |
UA81649C2 (ru) | Эфиры карбаминовой кислоты, которые имеют антихолинергическое действие | |
ATE554793T1 (de) | Konjugat | |
ZA200507966B (en) | A method for oxygen regulated production of recombinant staphylokinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |